Anaplastic extramedullary plasmacytoma resistant to novel therapies: a case report
Author:
Jacevičiūtė Emilija1, Rudžianskienė Milda2, Dambrauskienė Rūta2, Vajauskas Donatas3, Gerbutavičius Rolandas2
Affiliation:
1. Faculty of Medicine, Medical Academy , Lithuanian University of Health Sciences , Kaunas , Lithuania 2. Department of Oncology and Hematology , Institute of Oncology, Faculty of Medicine, Medical Academy, Lithuanian University of Health Sciences , Kaunas , Lithuania 3. Department of Radiology, Faculty of Medicine , Medical Academy, Lithuanian University of Health Sciences , Kaunas , Lithuania
Abstract
Abstract
Objectives
The treatment of choice for extramedullary plasmacytoma (EMP) is radiotherapy (RT). It is under discussion whether the management of an anaplastic form of EMP requires the addition of systemic therapy.
Case presentation
We present a case of a 66-year-old male who was diagnosed with anaplastic plasmacytoma of the maxillary sinus. After the exclusion of multiple myeloma, Dara-VMP (daratumumab, bortezomib, melphalan, and prednisolone) regimen was initiated. During the third cycle of Dara-VMP, a progression of the tumor was observed. RT and BRd (bendamustine, dexamethasone, and lenalidomide) regimen were initiated. After 4 cycles of BRd, disease progression was established. KRd (carfilzomib, lenalidomide, and dexamethasone) regimen was initiated. The first cycle of KRd was not completed, as the patient was diagnosed with COVID-19. After the infection, the progression of EMP was observed.
Conclusions
In this case, the anaplastic EMP was resistant to RT and chemotherapy regimens with novel agents, including a monoclonal antibody, an immunomodulatory drug, and proteasome inhibitors.
Publisher
Walter de Gruyter GmbH
Reference23 articles.
1. Rajkumar, SV, Dimopoulos, MA, Palumbo, A, Blade, J, Merlini, G, Mateos, MV, et al.. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538–48. https://doi.org/10.1016/s1470-2045(14)70442-5. 2. Holler, A, Cicha, I, Eckstein, M, Haderlein, M, Pöttler, M, Rappl, A, et al.. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts—a follow-up. Cancer Med 2022;11:4743–55. https://doi.org/10.1002/cam4.4816. 3. Caers, J, Paiva, B, Zamagni, E, Leleu, X, Bladé, J, Kristinsson, SY, et al.. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European expert panel. J Hematol Oncol 2018;11:10. https://doi.org/10.1186/s13045-017-0549-1. 4. Pham, A, Mahindra, A. Solitary plasmacytoma: a review of diagnosis and management. Curr Hematol Malig Rep 2019;14:63–9. https://doi.org/10.1007/s11899-019-00499-8. 5. Xing, MH, Shaari, AL, Beute, JE, Mundi, N, Matloob, A, Khorsandi, AS, et al.. Rare case of anaplastic plasmacytoma in the sinonasal tract. Head Neck 2021;43:E46–50. https://doi.org/10.1002/hed.26818.
|
|